JP6162709B2 - シチジンアナログの経口製剤を使用して癌を治療する方法 - Google Patents

シチジンアナログの経口製剤を使用して癌を治療する方法 Download PDF

Info

Publication number
JP6162709B2
JP6162709B2 JP2014540046A JP2014540046A JP6162709B2 JP 6162709 B2 JP6162709 B2 JP 6162709B2 JP 2014540046 A JP2014540046 A JP 2014540046A JP 2014540046 A JP2014540046 A JP 2014540046A JP 6162709 B2 JP6162709 B2 JP 6162709B2
Authority
JP
Japan
Prior art keywords
azacytidine
subject
day
cytidine analog
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014540046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532704A5 (enExample
JP2014532704A (ja
Inventor
ジェイ．マクベス カイル
ジェイ．マクベス カイル
エヌ．ヌグイエン アアロン
エヌ．ヌグイエン アアロン
ディマルティノ ジョルゲ
ディマルティノ ジョルゲ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2014532704A publication Critical patent/JP2014532704A/ja
Publication of JP2014532704A5 publication Critical patent/JP2014532704A5/ja
Application granted granted Critical
Publication of JP6162709B2 publication Critical patent/JP6162709B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014540046A 2011-11-01 2012-10-31 シチジンアナログの経口製剤を使用して癌を治療する方法 Active JP6162709B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554344P 2011-11-01 2011-11-01
US61/554,344 2011-11-01
PCT/US2012/062845 WO2013067043A1 (en) 2011-11-01 2012-10-31 Methods for treating cancers using oral formulations of cytidine analogs

Publications (3)

Publication Number Publication Date
JP2014532704A JP2014532704A (ja) 2014-12-08
JP2014532704A5 JP2014532704A5 (enExample) 2015-12-03
JP6162709B2 true JP6162709B2 (ja) 2017-07-12

Family

ID=47146759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540046A Active JP6162709B2 (ja) 2011-11-01 2012-10-31 シチジンアナログの経口製剤を使用して癌を治療する方法

Country Status (17)

Country Link
US (2) US9125884B2 (enExample)
EP (1) EP2773322A1 (enExample)
JP (1) JP6162709B2 (enExample)
KR (1) KR20140088603A (enExample)
CN (1) CN104168884A (enExample)
AU (1) AU2012318239B2 (enExample)
BR (1) BR112014010417A2 (enExample)
CA (1) CA2853949A1 (enExample)
EA (1) EA201490911A1 (enExample)
HK (1) HK1200716A1 (enExample)
IL (1) IL232268A0 (enExample)
MX (1) MX2014005314A (enExample)
PH (1) PH12014500965A1 (enExample)
SG (1) SG11201401946QA (enExample)
TW (2) TWI558401B (enExample)
WO (1) WO2013067043A1 (enExample)
ZA (2) ZA201403106B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161593A (en) 2008-05-15 2017-04-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
EP3094744A1 (en) * 2014-01-15 2016-11-23 Apogenix AG Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195786A2 (en) * 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
CN104147036B (zh) * 2014-08-24 2017-04-05 浙江大学 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用
TWI690333B (zh) * 2015-06-29 2020-04-11 日商大賽璐股份有限公司 易服用性固態製劑（有核錠）之製造方法及易服用性固態製劑
TWI716415B (zh) * 2015-06-29 2021-01-21 日商大賽璐股份有限公司 易服用性固態製劑之製造方法及易服用性固態製劑
CN108472280A (zh) * 2015-09-01 2018-08-31 布罗德研究所股份有限公司 用于治疗或者预防血液癌症的化合物和方法
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017180768A1 (en) * 2016-04-15 2017-10-19 Seattle Genetics, Inc. Combinations of cd33 antibody drug conjugates with hypomethylating agents
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
IL262565B (en) * 2016-06-06 2022-08-01 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
WO2018009705A1 (en) * 2016-07-06 2018-01-11 Youhealth Biotech, Limited Liver cancer methylation markers and uses thereof
US12016902B2 (en) 2017-04-04 2024-06-25 Loma Linda University Biologic for the treatment of cancer
GB201819453D0 (en) * 2018-11-29 2019-01-16 Ucl Business Plc Molecular signature
CA3156376A1 (en) 2019-11-04 2021-05-14 Fei Huang Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms
KR20230113186A (ko) * 2022-01-21 2023-07-28 주식회사 피노바이오 5-아자-4'-티오-2'-데옥시사이티딘을 함유하는 경구용 제형 및 이의 제조방법
WO2024191252A1 (ko) * 2023-03-14 2024-09-19 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69831335T3 (de) 1997-06-06 2015-01-15 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
WO2004041195A2 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615292A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
SI1931321T1 (sl) 2005-08-31 2019-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
US20080182806A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
WO2009042766A1 (en) 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
WO2009126401A1 (en) 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
MY161593A (en) * 2008-05-15 2017-04-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
EP2361085B9 (en) * 2008-11-22 2019-01-02 F.Hoffmann-La Roche Ag Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
US8492361B2 (en) 2009-02-10 2013-07-23 Celgene Corporation Methods for treating non-small cell lung cancer using 5-azacytidine
CN105832703A (zh) 2010-06-07 2016-08-10 阿布拉科斯生物科学有限公司 治疗增殖性疾病的联合治疗方法
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof

Also Published As

Publication number Publication date
EP2773322A1 (en) 2014-09-10
TW201325598A (zh) 2013-07-01
MX2014005314A (es) 2014-09-08
AU2012318239A1 (en) 2013-05-16
US9125884B2 (en) 2015-09-08
KR20140088603A (ko) 2014-07-10
US20150216886A1 (en) 2015-08-06
CN104168884A (zh) 2014-11-26
BR112014010417A2 (pt) 2014-11-18
NZ624323A (en) 2016-07-29
SG11201401946QA (en) 2014-05-29
TW201700103A (zh) 2017-01-01
JP2014532704A (ja) 2014-12-08
CA2853949A1 (en) 2013-05-10
PH12014500965A1 (en) 2014-06-30
US9693987B2 (en) 2017-07-04
EA201490911A1 (ru) 2014-09-30
TWI558401B (zh) 2016-11-21
IL232268A0 (en) 2014-06-30
ZA201403106B (en) 2015-08-26
ZA201502909B (en) 2016-11-30
US20130109644A1 (en) 2013-05-02
HK1200716A1 (zh) 2015-08-14
AU2012318239B2 (en) 2015-07-09
WO2013067043A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
JP6162709B2 (ja) シチジンアナログの経口製剤を使用して癌を治療する方法
JP6426778B2 (ja) シチジン類似体の経口製剤およびその使用方法
JP2017526700A (ja) 抗ｐｄ１若しくは抗ｐｄｌ１モノクローナル抗体と組み合わせてシチジン類似体の経口製剤を使用する疾患または障害の治療方法
US20150359810A1 (en) Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US20140357567A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
US20160250246A1 (en) Oral formulations of cytidine analogs and methods of use thereof
WO2015195786A2 (en) Methods for treating cancers using oral formulations of cytidine analogs
AU2015234311A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
NZ624323B2 (en) Methods for treating cancers using oral formulations of cytidine analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170615

R150 Certificate of patent or registration of utility model

Ref document number: 6162709

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250